Unique vaccine approach

Spores to Help Combat Coronavirus

Virologist Cornel Fraefel hopes a novel vaccine technique will help control Sars-CoV-2. The Swiss National Science Foundation has awarded him a grant to fund the remarkable project.

Stefan Stöcklin

Sars CoV 2
Sars CoV 2
The distinctive envelope proteins of the virus are the focus of Cornel Fraefel's vaccine project from the Vetsuisse Faculty. (Bild: istock/narvikk) (Image: istock/narvikk)


There's optimism in the air in Cornel Fraefel's lab. His team have just found out that their coronavirus vaccine project has been awarded a grant of half a million Swiss francs by the Swiss National Science Foundation. The virologist from the Vetsuisse Faculty convinced the expert panel of his novel approach using bacterial spores, and his proposal was approved. "We're over the moon," says the usually reserved scientist, enthusiastically. To demonstrate the uniqueness of this approach, you only need to look at the World Health Organization's long list of candidate vaccines, which comprises more than 160 projects, 28 of which are already in the first phase of clinical trials. But not a single one of these projects uses the route that Fraefel and his colleagues Claudio Aguilar and Catherine Eichwald are using.

Oral vaccination

What the researchers are aiming for is a vaccine delivered via the spores of the bacterium Bacillus subtilis – a vaccine that you could just swallow and not have to inject into the blood. The microscopic spores are heat-stable and resistant to environmental conditions and can thus be stored and transported easily. Unlike many other vaccines, they do not require costly refrigeration, which makes them easier to use in rural areas in developing countries, for example. Once swallowed, the spores of B. subtilis pass through the stomach and develop their immunisation protection in the small intestine. In short, spores are the ideal dosage form for a vaccine, if they work.

And Cornel Fraefel is convinced they do. The immunisation protection is based on a genetic modification of the bacterial genome to insert the gene sequences of the Sars-CoV-2 envelope protein. The bacteria modified in this way are then cultivated in a shaker for several days in a lab to stimulate the formation of spores. The ball-shaped spores are extremely resistant and enter a sort of dormant state to survive hostile environmental conditions. If these spores are then ingested, they pass through the stomach and germinate in the small intestine. This results in a bacterial film, which contains the coronavirus protein antigens. The human immune system reacts in the same way as with a conventional vaccine by producing antibodies and memory or helper cells – at least this is the expectation.

Bacillus subtilis
Bacillus subtilis
The picture shows a layer/biofilm of B.subtilis bacteria in a Petri dish. (Image: Claudio Aguilar)


"The process works in principle and has been successful in initial vaccines in the veterinary field," says Cornel Fraefel. His team have already developed a vaccine against dog tapeworm in this way. A good immune response – including the production of various types of immunoglobulins and a T-cell response – were detected in animal trials, which raises hope of an effective vaccine for humans.

Safe for the environment

Biological safety is a specific consideration in this project: Because genetically modified bacteria/bacterial spores are used, it is important to ensure that they cannot multiply if they are inadvertently released into the environment. Fraefel's team therefore developed a biocontainment system by modifying the genetic material to ensure that the microbes can no longer multiply if they are released.

Thanks to the SNSF grant, Fraefel's team are now working flat out to develop the promising vaccine. The genetic construction of B. subtilis is likely to take two to three months. This will be followed by studies on the immune response and safety in animals, with the participation of coronavirus expert Volker Thiel from the University of Bern. If everything goes according to plan, the vaccine candidate should then be tested on humans. This will show whether the new technique lives up to expectations. If a suitable vaccine looks likely, industrial partners will need to get on board and back the project.


UZH Research at the NRP 78 "COVID-19"

Cornel Fraefel's vaccine project is one of seven UZH projects that the Swiss National Science Foundation approved as part of NRP 78 “COVID-19” at the end of July 2020. Another UZH project also involves a vaccine and takes the now well-known naked RNA approach. The other projects in life sciences deal with the biological and medical aspects of the pandemic. One of the seven projects is in social sciences and looks at behavior of the public and prevention.

The SNSF points out that the selection procedure involving an expert panel was "extremely competitive". A total of 188 projects were submitted by all Swiss universities, and the experts selected the best 28. A quarter of the approved projects are being conducted by researchers at UZH. The details of the projects can be found on the SNSF COVID-19 project registry for NRP 78.

Stefan Stöcklin, editor UZH News; English translation by Gemma Brown

Write Comment

The editorial team reserves the right to not publish comments. We will not publish anonymous, defamatory, racist, sexist, otherwise prejudiced, or irrelevant comments. UZH News will also not publish comments with advertising content.

Number of remaining characters: 1000